A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Lead Sponsor

Eisai Co., Ltd.

Age

20 - 74 years

Sex

FEMALE

Healthy Volunteers

No

•Females aged greater than or equal to 20 years and less than 75 years at the time of informed consent.
•Histologically or cytologically confirmed with breast cancer
•Score 3+ by immunohistochemistry (IHC) or HER2 positive by Fluorescence in Situ Hybridization (FISH) method
•Subjects who meet any of the following criteria:
•* Evidence of recurrence during adjuvant chemotherapy with trastuzumab and taxane
•* Evidence of recurrence within 6 months after adjuvant chemotherapy with trastuzumab and taxane
•* Experienced prior chemotherapy including trastuzumab and taxane for advanced or recurrent breast cancer
•Adequate organ function
•Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) is 0 or 1
•Subjects who have submitted written informed consent for study entry

•Subjects with known brain metastasis accompanied by clinical symptoms or requiring active treatment
•Subjects with severe active infection requiring active treatment
•Subjects with large pleural effusions, ascites, or pericardial effusions requiring drainage.
•Hypersensitivity to trastuzumab, halicondrin B or halicondrin B chemical derivatives
•Known positive for human immunodeficiency virus (HIV) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV) by serum test.
•Subjects who are pregnant (positive B-hCG test) or breastfeeding
•Subjects judged to be ineligible for this study by the principal investigator or sub-investigator.

Related studies

NCT07586215 · Breast Cancer Metastatic

NCT05831878 · Advanced Breast Cancer

NCT07368998 · Breast Cancer

NCT07578064 · Breast Cancer, Bone Marrow Suppression

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more